Provided by Tiger Fintech (Singapore) Pte. Ltd.

CERo Therapeutics Holdings, Inc.

1.99
-0.3800-16.03%
Post-market: 2.030.0400+2.01%19:58 EDT
Volume:428.15K
Turnover:912.51K
Market Cap:2.40M
PE:-0.06
High:2.37
Open:2.31
Low:1.93
Close:2.37
52wk High:895.40
52wk Low:1.93
Shares:1.21M
Float Shares:1.15M
Volume Ratio:0.58
T/O Rate:37.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-35.0792
EPS(LYR):-434.4641
ROE:--
ROA:-156.89%
PB:-0.23
PE(LYR):0.00

Loading ...

Company Profile

Company Name:
CERo Therapeutics Holdings, Inc.
Exchange:
NASDAQ
Establishment Date:
2021
Employees:
- -
Office Location:
201 Haskins Way,Suite 230,South San Francisco,California,United States
Zip Code:
94080
Fax:
- -
Introduction:
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies. The company was incorporated in 2021 and is based in South San Francisco, California.

Directors

Name
Position
Chris Ehrlich
Chairman, Chief Executive Officer, Director
Brian G. Atwood
Director
Kathleen LaPorte
Director
Lindsey Rolfe
Director
Michael Byrnes
Director
Shami Patel
Director

Shareholders

Name
Position
Chris Ehrlich
Chairman, Chief Executive Officer, Director
Andrew Kucharchuk
Chief Financial Officer
Kristen Pierce
Chief Development Officer